Scatter plots of photo score by ColorDx green cone score (A), red cone score (B), and blue cone score (C). by Richard C. Trevino (22676460)

Supplementary file 1_Hydroxysafflor yellow A alleviates oxidative stress and inflammatory damage in the livers of mice with nonalcoholic fatty liver disease and modulates gut micro... by Liang Wu (131111)

“…Gut microbiota analysis revealed a significant increase in the abundance of Turicibacter, while a reduction of Ruminococcus. …”

AVAcore placement. by Jacob P. Rastas (20642173)

S1 File - by Jacob P. Rastas (20642173)

“…<div><p>Temperature regulation in dogs is significantly impaired during general anesthesia. Glabrous skin on paws may facilitate thermoregulation from this area and is a potential target for interventions attenuating hypothermia. …”

Effects of pre-medication and warming device on heart rate (HR) assessed by pulse oximetry in dogs following pre-medication, induction and inhalant anesthesia. by Jacob P. Rastas (20642173)

Times to tracheal extubation, sternal recumbency and standing (minutes) following inhalant anesthesia and final rectal temperatures (°C) in each premedication-treatment group. by Jacob P. Rastas (20642173)

Non-linear relationship between urinary cadmium and bone mineral density from the adjusted restricted cubic splines model. by Aroon La-up (14095691)

ASMR (A), ASDR (B), Age-Standardized Rate of YLDs (C), and Age-Standardized Rate of YLLs (D) of high alcohol use-related Stroke in both sexes combined in global in 2021. by Nannan Qian (10650782)

Data Sheet 1_Neuronal expression of S100B triggered by oligomeric Aβ peptide contributes to protection against cytoskeletal damage and synaptic loss.docx by Joana Saavedra (11327910)

“…We used the AD mouse model AβPPswe/PS1A246E to show that neuronal S100B levels are significantly higher in 10-month-old animals, and cellular assays to demonstrate that Aβ oligomers significantly increase S100B expression in SH-SY5Y cells, but not monomeric or fibrillar Aβ. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…Benchmark concentration analysis of transcriptomic responses at 4 dph, based on the most sensitive transcriptomic features, yielded tPODs between 0.028 and 0.47 μg/L B[<i>a</i>]P. At 28 dph, Cyp1a1 exhibited significantly increased catalytic activity, with biochemical POD, bPOD_EROD,28dph of 0.599 μg/L B[<i>a</i>]P, while morphometric analysis showed significant growth inhibition in terms of length, with apical POD, aPOD_length,28dph of 1.77 μg/L B[<i>a</i>]P, with a notable decreasing trend in body weight. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…Benchmark concentration analysis of transcriptomic responses at 4 dph, based on the most sensitive transcriptomic features, yielded tPODs between 0.028 and 0.47 μg/L B[<i>a</i>]P. At 28 dph, Cyp1a1 exhibited significantly increased catalytic activity, with biochemical POD, bPOD_EROD,28dph of 0.599 μg/L B[<i>a</i>]P, while morphometric analysis showed significant growth inhibition in terms of length, with apical POD, aPOD_length,28dph of 1.77 μg/L B[<i>a</i>]P, with a notable decreasing trend in body weight. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…Benchmark concentration analysis of transcriptomic responses at 4 dph, based on the most sensitive transcriptomic features, yielded tPODs between 0.028 and 0.47 μg/L B[<i>a</i>]P. At 28 dph, Cyp1a1 exhibited significantly increased catalytic activity, with biochemical POD, bPOD_EROD,28dph of 0.599 μg/L B[<i>a</i>]P, while morphometric analysis showed significant growth inhibition in terms of length, with apical POD, aPOD_length,28dph of 1.77 μg/L B[<i>a</i>]P, with a notable decreasing trend in body weight. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…Benchmark concentration analysis of transcriptomic responses at 4 dph, based on the most sensitive transcriptomic features, yielded tPODs between 0.028 and 0.47 μg/L B[<i>a</i>]P. At 28 dph, Cyp1a1 exhibited significantly increased catalytic activity, with biochemical POD, bPOD_EROD,28dph of 0.599 μg/L B[<i>a</i>]P, while morphometric analysis showed significant growth inhibition in terms of length, with apical POD, aPOD_length,28dph of 1.77 μg/L B[<i>a</i>]P, with a notable decreasing trend in body weight. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…Benchmark concentration analysis of transcriptomic responses at 4 dph, based on the most sensitive transcriptomic features, yielded tPODs between 0.028 and 0.47 μg/L B[<i>a</i>]P. At 28 dph, Cyp1a1 exhibited significantly increased catalytic activity, with biochemical POD, bPOD_EROD,28dph of 0.599 μg/L B[<i>a</i>]P, while morphometric analysis showed significant growth inhibition in terms of length, with apical POD, aPOD_length,28dph of 1.77 μg/L B[<i>a</i>]P, with a notable decreasing trend in body weight. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…Benchmark concentration analysis of transcriptomic responses at 4 dph, based on the most sensitive transcriptomic features, yielded tPODs between 0.028 and 0.47 μg/L B[<i>a</i>]P. At 28 dph, Cyp1a1 exhibited significantly increased catalytic activity, with biochemical POD, bPOD_EROD,28dph of 0.599 μg/L B[<i>a</i>]P, while morphometric analysis showed significant growth inhibition in terms of length, with apical POD, aPOD_length,28dph of 1.77 μg/L B[<i>a</i>]P, with a notable decreasing trend in body weight. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…Benchmark concentration analysis of transcriptomic responses at 4 dph, based on the most sensitive transcriptomic features, yielded tPODs between 0.028 and 0.47 μg/L B[<i>a</i>]P. At 28 dph, Cyp1a1 exhibited significantly increased catalytic activity, with biochemical POD, bPOD_EROD,28dph of 0.599 μg/L B[<i>a</i>]P, while morphometric analysis showed significant growth inhibition in terms of length, with apical POD, aPOD_length,28dph of 1.77 μg/L B[<i>a</i>]P, with a notable decreasing trend in body weight. …”

Data Sheet 1_Landscape analysis of m6A modification regulators reveals LRPPRC as a key modulator in tubule cells for DKD: a multi-omics study.docx by Li Jiang (120930)

“…The significance of N6-methyladenosine (m6A) modification in the pathogenesis of DKD has become increasingly prominent.…”

Table 3_Multi-omics reveals that NOTCH1 promotes cervical cancer progression and reduces radiosensitivity.xlsx by Aihua Guo (13267712)

“…</p>Conclusions<p>This study clarifies NOTCH1’s role in promoting cervical cancer progression and reducing radiosensitivity, with has-miR-449a as a negative regulator, providing targets for optimizing cervical cancer radiotherapy.…”

Table 1_Multi-omics reveals that NOTCH1 promotes cervical cancer progression and reduces radiosensitivity.docx by Aihua Guo (13267712)

“…</p>Conclusions<p>This study clarifies NOTCH1’s role in promoting cervical cancer progression and reducing radiosensitivity, with has-miR-449a as a negative regulator, providing targets for optimizing cervical cancer radiotherapy.…”

Table 2_Multi-omics reveals that NOTCH1 promotes cervical cancer progression and reduces radiosensitivity.docx by Aihua Guo (13267712)

“…</p>Conclusions<p>This study clarifies NOTCH1’s role in promoting cervical cancer progression and reducing radiosensitivity, with has-miR-449a as a negative regulator, providing targets for optimizing cervical cancer radiotherapy.…”